title: Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha.
abstract: Thalidomide is effective in the treatment of inflammatory conditions like erythema nodosum leprosum in leprosy patients, and aphthous ulcers in AIDS patients. Its mechanism of action is uncertain and reports of its effect on the synthesis of inflammatory cytokines such as IL-2 and TNF-alpha are contradictory. As thalidomide is labile to spontaneous hydrolysis at pH 7.4, studies were carried out to explore the effects of deliberate hydrolysis or the ability of thalidomide to modulated cytokine production by human mononuclear cells stimulated in vitro with Staphylococcal enterotoxin A (SEA)(IL-2) or lipopolysaccharide from Salmonella minnesota (LPS)(TNF-alpha). Unhydrolyzed thalidomide at 4.0 micrograms/ml consistently enhanced the synthesis of IL-2 in SEA-stimulated cells, and suppressed the synthesis of TNF-alpha in LPS-stimulated cells; whereas, hydrolyzed thalidomide had no enhancing effect on SEA stimulated-cell synthesis of IL-2 or suppressive effect on LPS stimulated-cell synthesis of TNF-alpha. These findings demonstrate that thalidomide's ability in vitro to enhance IL-2 and to suppress TNF-alpha in stimulated cells is dependent on the intact molecule and underscore the necessity to employ thalidomide under appropriate physicochemical conditions.
authors.affiliation: Laboratory Research Branch, G.W.L. Hansen's Disease Center, LSU, Baton Rouge 70894, USA.
authors.forename: E J
authors.initials: EJ
authors.lastname: Shannon
authors.forename: F
authors.initials: F
authors.lastname: Sandoval
authors.forename: J L
authors.initials: JL
authors.lastname: Krahenbuhl
mesh_terms: D001711:Biotransformation; D005260:Female; D006801:Humans; D006868:Hydrolysis; D007376:Interleukin-2 / Q000096:biosynthesis* / Q000097:blood; D007917:Leprostatic Agents / Q000378:metabolism* / Q000493:pharmacokinetics*; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D013268:Stimulation, Chemical; D013792:Thalidomide / Q000378:metabolism* / Q000493:pharmacokinetics*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
chemical_list: D007376:Interleukin-2; D007917:Leprostatic Agents; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide